BNOX Stock Overview
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Bionomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.01 |
| 52 Week High | US$6.41 |
| 52 Week Low | US$0.87 |
| Beta | -0.092 |
| 1 Month Change | -1.94% |
| 3 Month Change | 4.34% |
| 1 Year Change | -54.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.14% |
Recent News & Updates
Shareholder Returns
| BNOX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.2% | 0.1% | 2.2% |
| 1Y | -54.9% | -1.0% | 22.8% |
Return vs Industry: BNOX underperformed the US Biotechs industry which returned -2.3% over the past year.
Return vs Market: BNOX underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| BNOX volatility | |
|---|---|
| BNOX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BNOX's share price has been volatile over the past 3 months.
Volatility Over Time: BNOX's weekly volatility has decreased from 38% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited Fundamentals Summary
| BNOX fundamental statistics | |
|---|---|
| Market cap | US$10.69m |
| Earnings (TTM) | -US$20.37m |
| Revenue (TTM) | US$434.80k |
24.8x
P/S Ratio-0.5x
P/E RatioIs BNOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNOX income statement (TTM) | |
|---|---|
| Revenue | AU$661.98k |
| Cost of Revenue | AU$16.58m |
| Gross Profit | -AU$15.92m |
| Other Expenses | AU$15.09m |
| Earnings | -AU$31.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | -2,405.04% |
| Net Profit Margin | -4,684.05% |
| Debt/Equity Ratio | 3.9% |
How did BNOX perform over the long term?
See historical performance and comparison